

## SUBJECT INDEX VOLUME 16

- A**
- ACTH, cocaine and, 399
  - Addiction, cocaine, 77
  - ADHD. *See* Attention deficit/hyperactivity disorder (ADHD)
  - $\alpha_2$ -Adrenoceptor antagonist, gender and, 298
  - Adrenocorticotrophic hormone (ACTH). *See* ACTH
  - $\beta$ -Adrenoreceptors, alcoholism, panic disorder and, 69
  - Affective disorders, lithium and, 408
  - Aggression, platelet 5-HT<sub>2A</sub> receptors and, 211
  - Aging, somatostatin effects on sleep, 339
  - Alcoholism,  $\beta$ -adrenoreceptors in panic disorder and, 69
  - Alpha-ethyltryptamine (AET), effects on prepulse inhibition (PPI) and startle habituation, 246
  - Alprazolam
    - CYP2C19 status and, 8
    - 5-mephenytoin 4-hydroxylation and, 8
    - smoking and, 8
  - Alzheimer's disease, thiopental and, 269
  - Amino acids, effects on tardive dyskinesia with schizophrenia, 136
  - d-Amphetamine, opiate-dopamine interactions, 147
  - Amphetamines, neonatal hippocampal lesion-induced behavioral hyperresponsiveness and, 259
  - Anticonvulsants, valproic acid, 238
  - Antipsychotic drugs, effects on dopamine D<sub>2</sub> and 5-HT<sub>2</sub> receptors, 1
  - AP-1, valproic acid and, 238
  - Attention, seligiline in attention deficit/hyperactivity disorder (ADHD) adults, 276
  - Attention deficit/hyperactivity disorder (ADHD), selegiline in adults, 276
  - Atypical antipsychotic drugs, olanzapine effects on dopamine D<sub>2</sub> and 5-HT<sub>2</sub> receptors, 1
- B**
- Beta activity, thiopental in dementia and, 269
  - Bipolar disorder
    - lithium and, 325
    - valproic acid and, 238
  - Blood platelets, serotonin receptors and, 285
  - Blood pressure, serotonin receptors and, 285
  - Body mass index, serotonin receptors and, 285
  - Body weight, serotonin receptors and, 285
  - Brain
    - lithium and carbamazepine effects on rat, 25
    - ventricular brain ratio, schizophrenia in drug-naive patients and, 51
- C**
- c-fos, binding assays, 238
  - c-jun, binding assays, 238
  - cAMP responsive element binding protein (CREB), valproic acid and, 238
  - Cannabinoids, prefrontal cortical catecholaminergic utilization, spatial working memory, and, 426
  - Carbamazepine, thyroid hormone metabolism and, 25
  - Catalepsy, atypical neuroleptics and, 93, 111, 114, 116, 123
  - Catecholamines, selective attention and, 202
  - CCK, social phobia and, 229
  - Cell membrane, lithium in bipolar disorder and, 325
  - Cerebrospinal fluid (CSF), levels in transforming growth factors with schizophrenia, 83
  - Chemical models, social phobia and, 229
  - m-Chlorophenylpiperazine (m-CCP), premenstrual dysphoric disorder (PMDD) and, 346
  - Cholecystokinin (CCK), social phobia and, 229
  - Cholinergic, lithium and basal and stimulated c-fos mRNA expression in rat brain, 408
  - Clonidine, selective attention and, 202
  - Clozapine
    - dopamine D<sub>2</sub> and D<sub>4</sub> receptors and, 93, 111, 114, 116, 123
    - prefrontal cortical cognitive defects and, 433
  - Cocaine
    - corticosterone blockade and, 156
    - gender and cocaine-induced HPA axis activation, 399
    - opiate-dopamine interactions, 147
    - sensitization, 77
  - Cognition
    - cannabinoids and, 426
    - cholinergic, dopaminergic, and serotonergic blockade effects, 15
    - clozapine and, 433
  - Contraceptives, oral, serotonin receptors and, 285
  - Cortical development, schizophrenia and, 385
  - Corticosterone, cocaine and, 156
  - Cortisol, D-cycloserine and, 317
  - CREB, valproic acid and, 238
  - D-Cycloserine, behavioral and neuroendocrine effects, 317
  - CYP2C19 status, alprazolam and, 8
  - Cytochrome P450
    - alprazolam and, 8
    - serotonin receptors and, 285
- D**
- Deiodinases, lithium and carbamazepine effects, 25
  - Delayed alteration, cannabinoids and, 426
  - Delayed response task, clozapine and, 433
  - Depression
    - diabetes and, 183
    - major, selective serotonin reuptake inhibitors (SSRI) effects on 5-HT<sub>1A</sub> agonists, 333
    - serotonin receptors in suicide victims, 162
    - tryptophan depletion and, 294
    - valproic acid and, 238
  - Diabetes, effects on dopamine and serotonin receptors, 183
  - Dopamine
    - clozapine and, 433
    - neuronal circuits and, 385
    - psychosis, 191
    - schizophrenia and, 61
  - Dopamine D<sub>1</sub> receptors, neonatal hippocampal lesions and, 259
  - Dopamine D<sub>2</sub> receptors
    - naloxone-precipitated withdrawal with opiate-dependence and, 174
    - neonatal hippocampal lesions and, 259
    - neuronal circuits and, 375
    - olanzapine effects on 5-HT<sub>2</sub> and, 1
  - Dopamine D<sub>3</sub> receptors, neuronal circuits and, 375
  - Dopamine D<sub>4</sub> receptors
    - atypical neuroleptics and, 93, 111, 114, 116, 123
    - neuronal circuits and, 375
  - Dopamine receptors, streptozotocin-induced diabetes effects, 183
  - Dopaminergic, lithium and basal and stimulated c-fos mRNA expression in rat brain, 408
  - Droperidol, selective attention and, 202
  - Drug-naive patients, schizophrenia in, 51
  - Drug therapy, bipolar disorder and, 325
- E**
- EEG, thiopental in dementia and, 269
  - EEG sleep, schizophrenia in drug-naive patients and, 51
  - ELISA, transforming growth factors and schizophrenia, 83
  - Event-related potential (ERP), selective attention and, 202
  - Eye movement, risperidone and haloperidol effects, 217
- F**
- Females, cocaine-induced HPA axis activation and, 399
  - First-episode schizophrenia, m-chlorophenyl-piperazine vs. methylphenidate, 61
  - <sup>18</sup>F-Fluoro-deoxyglucose (FDG), gender and idazoxon effects, 298
  - [F-18]-Fluorodeoxyglucose (FDG), psilocybin model of psychosis, 357

- F**  
**Fluoxetine**  
 alpha-ethyltryptamine (AET) effects on startle habituation and, 246  
 effects on extracellular norepinephrine in hippocampus, 419  
 premenstrual dysphoric disorder (PMDD) and, 346  
 Follicular phase, fluoxetine and, 346  
 c-fos mRNA expression, lithium and, 408  
 Fuller, Ray, in memoriam, 256
- G**  
**Gender**, cocaine-induced HPA axis activation and, 399  
**GHRH**, somatostatin and sleep effects in elderly and, 339  
**Growth hormone-releasing hormone (GHRH)**. *See* GHRH
- H**  
**Habituation**, alpha-ethyltryptamine (AET) and, 246  
**Haloperidol**  
 cognitive and behavioral effects, 15  
 effects on dopamine and serotonin receptors, 183  
 saccadic eye movements and, 217  
**Heterogeneity**, dopamine psychosis, 191  
**Hippocampus**  
 dopamine receptors and, 259  
 serotonin receptors in suicide victims with depression and, 162  
**Homovanillic acid**, psychosis, 191  
**HPA axis activation**, gender and cocaine-induced, 399  
**5-HT agonists**, alpha-ethyltryptamine (AET) effects on startle habituation and, 246  
**5-HT<sub>1A</sub> agonists**, selective serotonin reuptake inhibitors (SSRI) effects, 333  
**5-HT<sub>2</sub> receptors**  
 olanzapine effects on dopamine D<sub>2</sub> and, 1  
 psilocybin model of psychosis, 357  
**Humans**  
 positron emission tomography study of 5-HT<sub>2</sub> and dopamine D<sub>2</sub> receptor occupancy, 1  
 psilocybin model of psychosis, 357  
**Hyperactivity**, seligiline in attention deficit/hyperactivity disorder (ADHD) adults, 276  
**Hypothalamo-pituitary-adrenal (HPA) axis**. *See* HPA axis
- I**  
**Idazoxan**, gender and responses to  $\alpha_2$ -adrenoceptor blockade, 298  
**Imidazoline**, gender and responses to  $\alpha_2$ -adrenoceptor blockade, 298  
**In memoriam**, Winokur, George, 438  
**In vivo microdialysis**, fluoxetine effects on extracellular norepinephrine in hippocampus, 419  
**Ion transport**, lithium in bipolar disorder and, 325
- L**  
**Latent inhibition**, neuroleptic-induced enhancement, 42  
**LH**, D-cycloserine and, 317
- Lithium**  
 basal and stimulated c-fos mRNA expression in rat brain and, 408  
 bipolar disorder and, 325  
 thyroid hormone metabolism and, 25
- Locomotion**  
 corticosterone blockade effects on cocaine, 156  
 dopaminergic agonists and antagonists and, 259  
 opiate-dopamine interactions and, 147
- Locus coeruleus**, fluoxetine effects on extracellular norepinephrine, 419
- Luteal phase**, fluoxetine and, 346
- Luteinizing hormone (LH)**. *See* LH
- Lysergic acid diethylamide**, serotonin receptors and, 285
- M**  
**M-chlorophenyl-piperazine**, schizophrenia and methylphenidate vs., 61  
**Major depression**, selective serotonin reuptake inhibitors (SSRI) effects on 5-HT<sub>1A</sub> agonists, 333  
**Mania**, valproic acid and, 238  
**MAOI**, attention deficit/hyperactivity disorder (ADHD) and, 276  
**Memory**, cannabinoids and, 426  
**Menstrual cycle**, serotonin receptors and, 285  
**Metabolism**, alprazolam and, 8  
**Metergoline**, cognitive and behavioral effects, 15  
**N-Methyl-D-Aspartate (NMDA) receptors**. *See* NMDA receptors  
**3,4-Methylenedioxy-N-methylamphetamine (MDMA)**, alpha-ethyltryptamine (AET) vs., 246  
**Methylphenidate**, schizophrenia and m-chlorophenyl-piperazine vs., 61  
**Metyrapone**, corticosterone blockade effects on cocaine and, 156  
**Microdialysis**, in vivo, fluoxetine effects on extracellular norepinephrine in hippocampus, 419  
**Monoamine metabolites**, attention deficit/hyperactivity disorder (ADHD) and, 276  
**Monoamines**, prefrontal cortical catecholaminergic utilization, spatial working memory, and, 426  
**Morphine**, opiate-dopamine interactions, 147
- N**  
**Naloxone**, dopamine D<sub>2</sub> receptors in opiate-dependence and, 174  
**Neonatal lesions**, dopamine receptors and, 259  
**Neuroleptic response**, homovanillic acid psychosis and, 191  
**Neuroleptics**  
 dopamine D<sub>2</sub> and D<sub>4</sub> receptors and, 93, 111, 114, 116, 123  
 latent inhibition and, 42  
 Neuronal circuits, schizophrenia and, 375, 385  
 Neurotoxins, neonatal hippocampal lesions and, 259  
**NMDA receptors**, behavioral and neuroendocrine effects, 317  
**Norepinephrine**, fluoxetine effects on extracellular, 419
- Nucleus accumbens**, opiate-dopamine interactions and, 147
- O**  
**Obsessive compulsive disorder (OCD)**, alpha-ethyltryptamine (AET) and, 246  
**Olanzapine**, effects on dopamine D<sub>2</sub> and 5-HT<sub>2</sub> receptors, 1
- P**  
**P3**, catecholamine transmission and, 202  
**Panic**, pentagastrin and, 229  
**Panic disorder**,  $\beta$ -adrenoreceptors in alcoholism and, 69  
**Parkinsonism**, atypical neuroleptics and, 93, 111, 114, 116, 123  
**Pentagastrin**, social phobia and, 229  
**PET**. *See* Positron emission tomography (PET)  
**Pharmacology**  
 M-chlorophenyl-piperazine, 61  
 methylphenidate, 61  
**Phenylalanine**, effects on tardive dyskinesia with schizophrenia, 136  
**Pindolol**, effects on 5-HT<sub>1A</sub> agonists for antidepressant response, 333  
**Plasma monoamines**, attention deficit/hyperactivity disorder (ADHD) and, 276  
**Platelet 5-HT<sub>2A</sub> receptors**, effects with personality disorder, 211  
**Positron emission tomography (PET)**  
 dopamine D<sub>2</sub> receptors in opiate-dependence and, 174  
 gender and  $\alpha_2$ -adrenoceptor blockade, 298  
 5-HT<sub>2</sub> and dopamine D<sub>2</sub> receptor occupancy, 1  
 psilocybin model of psychosis, 357  
**Prefrontal cortex**  
 cannabinoids and, 426  
 clozapine and, 433  
 schizophrenia and, 385  
 serotonin receptors in suicide victims with depression and, 162  
**Prepulse inhibition (PPI)**, alpha-ethyltryptamine (AET) and, 246  
**Probes**, M-chlorophenyl-piperazine vs. methylphenidate in schizophrenia, 61  
**Processing negativity**, catecholamine transmission and, 202  
**Psilocybin**, psychosis model, 357  
**Psychomimetics**, prefrontal cortical catecholaminergic utilization, spatial working memory, and, 426  
**Psychomotor effects**, corticosterone blockade effects on cocaine, 156  
**Psychopathology**, psilocybin model of psychosis, 357  
**Psychosis**  
 cocaine, 77  
 dopamine, 191  
 psilocybin model, 357  
**Pyramidal neurons**, schizophrenia and, 385
- R**  
**Rapid eye movement latency**, schizophrenia in drug-naive patients and, 51  
**Rats**  
 lithium and basal and stimulated c-fos mRNA expression, 408  
 lithium and carbamazepine effects, 25

neuroleptic-induced enhancement of latent inhibition, 42  
 Receptors, serotonin, binding variability, 285  
 Relapse  
   cocaine addiction, 77  
   former depressed patients and tryptophan depletion, 294  
 REM sleep, elderly and somatostatin, 339  
 Risperidone, saccadic eye movements and, 217

## S

S-mephenytoin 4-hydroxylation, alprazolam and, 8  
 Saccades, risperidone and haloperidol effects, 217  
 Schizophrenia  
   clozapine and, 433  
   D-cycloserine and, 317  
   dopamine psychosis and, 191  
   dopamine receptors and, 375, 385  
   EEG sleep in drug-naive patients, 51  
   m-chlorophenyl-piperazine vs. methylphenidate, 61  
   phenylalanine effects with tardive dyskinesia and, 136  
   premenstrual dysphoric disorder (PMDD) and, 346  
   psilocybin model of psychosis, 357  
   transforming growth factors and, 83  
 Scopolamine, cognitive and behavioral effects, 15  
 Seasons, serotonin receptors and, 285  
 Selective attention, catecholamine transmission and, 202  
 Selective serotonin reuptake inhibitors (SSRI), effects on 5-HT<sub>1A</sub> agonists for antidepressant response, 333  
 Seligiline, attention deficit/hyperactivity disorder (ADHD) adults and, 276

Sensitization  
   cocaine, 77  
   opiate-dopamine interactions, 147  
 Serotonin  
   aggression in personality disorder and, 211  
   alpha-ethyltryptamine (AET) effects on startle habituation and, 246  
   schizophrenia and, 61  
   tryptophan depletion in former depressed patients and, 294  
 Serotonin receptors  
   streptozotocin-induced diabetes effects, 183  
   suicide victims with depression and, 162  
 Serotonin<sub>2</sub> receptors, atypical neuroleptics and, 93, 111, 114, 116, 123  
 Sex characteristics,  $\alpha_2$ -adrenoceptor blockade and, 298  
 Side effects, risperidone and haloperidol, 217  
 Signal transduction, lithium and basal and stimulated *c-fos* mRNA expression in rat brain, 408  
 Sleep  
   elderly and somatostatin, 339  
   slow wave, schizophrenia in drug-naive patients and, 51  
 Sleep endocrinology, elderly and somatostatin, 339  
 Slow wave sleep, schizophrenia in drug-naive patients and, 51  
 Smoking, alprazolam and, 8  
 Social interaction, pentagastrin and, 229  
 Somatostatin, sleep effects in elderly, 339  
 Startle habituation, alpha-ethyltryptamine (AET) and, 246  
 Streptozotocin, -induced diabetes, effects on dopamine and serotonin receptors, 183  
 Stress  
   clozapine and, 433

fluoxetine effects on extracellular norepinephrine in hippocampus and, 419  
 lithium and basal and stimulated *c-fos* mRNA expression in rat brain, 408  
 Suicide, serotonin receptors and, 162  
 Switching, neuroleptics, 42

## T

Tardive dyskinesia  
   diabetes and, 183  
   phenylalanine in schizophrenia with, 136  
 Thiopental, Alzheimer's type dementia and, 269  
 Thyroid hormones, lithium and carbamazepine effects, 25  
 Transcription factors, valproic acid and, 238  
 Transforming growth factors, schizophrenia and, 83  
 Tricyclic antidepressants, effects on 5-HT<sub>1A</sub> agonists for antidepressant response, 333  
 Tryptophan depletion, former depressed patients and, 294

## V

Valproic acid, AP-1 transcription factor DNA binding activity and, 238  
 Vascular dementia, thiopental and, 269  
 Ventricular brain ratio, schizophrenia in drug-naive patients and, 51

## W

Winokur, George, in memoriam, 438  
 Withdrawal, dopamine D<sub>2</sub> receptors in opiate-dependence and, 174